logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Ionis, the FDA and the exaggerated selloff of the firm's stock

A complete response letter (CRL) sent by The Division of Metabolism and Endocrinology Products of the United States’ FDA to Ionis Pharmaceuticals (IONS) and its affiliate Akcea Therapeutics (AKCA) regarding Waylivra™ (volanesorsen) carried like usual bad news. The FDA has...

Read More

August 30, 2018

0

Regenxbio, Moderna Therapeutics and Other Biotech Stocks Posted Gains in a Bad Market Day

Regenxbio, Moderna and Others Regenxbio ( RGNX ) announced several poster presentations including interim data from its Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II ( MPS II ), and family surveys focused on patients with...

Read More

January 30, 2020

0

About RegenxBio's Agreement with Clearside Biomedical and More

Diseases of the Back of the Eye Diseases of the back of the eye, such as: age-related wet macular degeneration, diabetic retinopathy and diabetic macular edema, are currently managed with injections of anti-vascular endothelial growth factor ( anti-VEGF ) drugs...

Read More

September 10, 2019

0

Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day

Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s really effective treatments. Three Calcitonin-gene-related peptide ( CGRP ) monoclonal antibody drugs have been approved in 2018 and 2019. They are: Aimovig for Amgen...

Read More

September 16, 2019

0

In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

As the Market Seems to Soar Our Eyes Are on the Following Biotech Firms: Amgen ( AMGN ) : A rebounding is expected following an unwarranted decline.   Gilead Sciences ( GILD ) : A lot of good news from the...

Read More

February 4, 2020

0

What happened to Sangamo yesterday?

The disease, mucopolysaccharidosis (MPS) type II, also known as the horrible Hunter syndrome is a killer with no specific treatment anywhere, except enzyme replacement therapy (ERT) that is not stopping the complications of the disease or preventing death. Sangamo (SGMO)...

Read More

September 6, 2018

0

Atara Allogeneic Product ATA188 Will Confirm Whether EBV Infecting B Cells Could Cause a Difficult to Treat Kind of MS

Atara Biotherapeutics ATA188 for MS Atara Biotherapeutics ( ATRA ) announced the presentation of initial efficacy data as well as updated safety results from its ongoing Phase 1 study of the firm’s product ATA188 for the treatment of a progressive...

Read More

September 17, 2019

0

Could Nektar Product NKTR-214 Become a Blockbuster?

Nektar Therapeutics NKTR-214: A Blockbuster? Nektar Therapeutics ( NKTR ) published preclinical data of its immuno-oncology candidate NKTR-214 bempegaldesleukin (bempeg) succeeded in revealing the details of the drug’s actions that led to its successful outcome when used in monotherapy or in...

Read More

February 4, 2020

0

At bluebird bio an Investigational Gene Therapy is Demonstrating Promising Results

bluebird bio Has Promising Results from Its Lenti-D Gene Therapy for CALD Good results have come from  bluebird bio’s ( BLUE ) updated results in the clinical development program for its investigational Lenti-D™ gene therapy in patients with cerebral adrenoleukodystrophy...

Read More

September 20, 2019

0

A Synopsis of Some Biotech Companies' Events

Synopsis The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems unfair and has proven to be. Amgen Amgen ( AMGN ) : The stock gained over $10 yesterday and is trading now at $231....

Read More

February 6, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 81
  • 82
  • 83
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy